Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A FTIH Study With GSK3008348 in Healthy Volunteers and Patients With Idiopathic Pulmonary Fibrosis

Next Previous
Search
Trial Profile

A FTIH Study With GSK3008348 in Healthy Volunteers and Patients With Idiopathic Pulmonary Fibrosis

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 06 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GSK 3008348 (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Adverse reactions; First in man
  • Sponsors GlaxoSmithKline; GSK

    • Most Recent Events

    • 12 Mar 2018 According to results published in the European Journal of Clinical Pharmacology, objectives of the study were achieved after the first two dosing periods in cohort 3; therefore, the study was terminated and the final two dosing periods in cohort 3 were not required.
    • 12 Mar 2018 Status changed from recruiting to discontinued.
    • 12 Mar 2018 Results (n=29) assessing safety, tolerability and pharmacokinetic (PK) profile of single doses of GSK3008348 in healthy participants, were published in the European Journal of Clinical Pharmacology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top